Drug Profile
AZD 8999
Alternative Names: AZD8999; LAS-190792; MABA long-acting; MABA1; Muscarinic antagonist-beta 2 agonist long actingLatest Information Update: 05 Nov 2023
Price :
$50
*
At a glance
- Originator Almirall S.A.
- Developer Almirall S.A.; AstraZeneca
- Class Antiasthmatics
- Mechanism of Action Beta 2 adrenergic receptor agonists; Muscarinic receptor antagonists
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
- New Molecular Entity Yes
Highest Development Phases
- Discontinued Asthma; Chronic obstructive pulmonary disease
Most Recent Events
- 09 Sep 2017 Adverse events, efficacy and pharmacokinetics data from a phase I trial in Chronic obstructive pulmonary disease presented at the 27th Annual Congress of the European Respiratory Society (ERS-2017)
- 29 Apr 2016 Discontinued - Phase-I for Asthma in United Kingdom (Inhalation)
- 29 Apr 2016 Discontinued - Phase-I for Chronic obstructive pulmonary disease in United Kingdom (Inhalation)